2024-03-07 08:33:11 ET
DENVER, Colo., Mar 07, 2024 ( 247marketnews.com )- IPA (NASDAQ: IPA ) reported, this morning, the development of a Foundation AI Model, which combines the strengths of Large Language Models (LLMs) through an advanced stacking technique with BioStrand’s patented HYFT Technology, representing a significant advancement in life sciences research and development.
Immunoprecise is trading at $ 2.15, up $0.57 (+36.08%), on 8M shares.
The integration of HYFT’s ability to pinpoint unique ‘fingerprints’ in biological sequences enables the stacked LLMs to apply their vast knowledge base with greater specificity, leading to more accurate predictions and insights, markeing a pivotal moment in the utilization of artificial intelligence for complex biological data analysis and drug discovery.
BioStrand’s Co-Founder and Head of Innovation, Dirk Van Hyfte MD, PhD, is scheduled to present findings live next week at the HIMSS24 conference in Orlando, Florida
“The development of our Foundation AI Model, powered by our unique ‘LLM stacking’ approach and patented HYFT technology, marks a significant milestone in the field of biotechnological research,” stated Van Hyfte. “This innovation not only expands the boundaries of current biotech research, but also establishes a new standard for the application of AI in solving complex biological challenges.”
“As the global community recognizes the transformative potential of artificial intelligence in the life sciences,” Hyfte continued, “I am confident that BioStrand’s Foundation AI Model will stand at the forefront of innovation and the future of AI-driven solutions in biology and drug discovery.”
The post BioStrand, IPA’s subsidiary, Reveals Major Life Sciences AI Model Breakthrough appeared first on 24/7 MarketNews .
For further details see:
BioStrand, IPA’s subsidiary, Reveals Major Life Sciences AI Model Breakthrough